Research programme: cannabinoid-2 receptor agonists - Pharmos
Alternative Names: PRS 211058; PRS-639,058Latest Information Update: 04 Mar 2011
Price :
$50 *
At a glance
- Originator Pharmos Corporation
- Class Cannabinoids
- Mechanism of Action Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Inflammation; Multiple sclerosis; Neuropathic pain; Pain; Psychiatric disorders; Rheumatoid arthritis
Most Recent Events
- 31 Dec 2010 Discontinued - Preclinical for Autoimmune disorders in Israel (unspecified route)
- 31 Dec 2010 Discontinued - Preclinical for Inflammation in Israel (unspecified route)
- 31 Dec 2010 Discontinued - Preclinical for Multiple sclerosis in Israel (unspecified route)